No Data
No Data
SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark
A Quick Look at Today's Ratings for SpringWorks Therapeutics(SWTX.US), With a Forecast Between $58 to $74
Barclays Sticks to Its Buy Rating for Springworks Therapeutics (SWTX)
Buy Rating Reaffirmed for Springworks Therapeutics Amid Promising Outlook for Ogsiveo and Mirdametinib
Optimistic Future for Springworks Therapeutics Amid Packaging Transition and Market Expansion
SpringWorks Therapeutics, Inc. (SWTX) Q3 2024 Earnings Call Transcript Summary